Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860642 | 0.92 | EPHX1 (0.39) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL28936386 | 0.90 | CYP4F2 (0.48) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL18597562 | 0.88 | CYP4F2 (0.39) | CYP4F2CYP4A11LMNAPOLB | |
| SCHEMBL25423570 | 0.87 | EPHX1 (0.44) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL15295458 | 0.86 | CYP4F2 (0.42) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL28730000 | 0.86 | EPHX1 (0.43) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL10939472 | 0.85 | EPHX1 (0.46) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| SCHEMBL5161537 | 0.84 | CA2 (0.62) | CYP4F2CYP4A11L3MBTL1ATMUSP2 | |
| SCHEMBL28162334 | 0.84 | EPHX1 (0.42) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL2538947 | 0.84 | EPHX1 (0.42) | CYP4F2CYP4A11EPHX1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287210-A1 | MARINE-BIODEGRADATION ACCELERATOR | NISSHINBO HOLDINGS INC. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-7268253-B2 | Process for preparing α, α-dialkyl-α-hydroxymethyl-carboxylic acid derivatives | CONSORTIUM FUER ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1666447-B1 | Process for the preparation of alpha, alpha-dialkyl, alpha-hydroxymethyl-carboxylic acid derivatives | CONSORTIUM ELEKTROCHEM IND (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060122424-A1 | Process for preparing alpha, alpha-dialkyl-alpha-hydroxymethyl-carboxylic acid derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1666447-A1 | Process for the preparation of alpha, alpha-dialkyl, alpha-hydroxymethyl-carboxylic acid derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1578714-A1 | NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID | Aventis Pharma S.A. (FR) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058678-A1 | NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID | AVENTIS PHARMA S.A (FR) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122424-A1 | Process for preparing alpha, alpha-dialkyl-alpha-hydroxymethyl-carboxylic acid derivatives | DDC, ADH1C, MCCC2 | CYP4F2 856/4885CYP4A11 658/4885EPHX1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.